These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30530600)

  • 1. Successful Treatment of Bacteremia Due to NDM-1-Producing
    Hobson CA; Bonacorsi S; Fahd M; Baruchel A; Cointe A; Poey N; Jacquier H; Doit C; Monjault A; Tenaillon O; Birgy A
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530600
    [No Abstract]   [Full Text] [Related]  

  • 2. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
    Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
    Veeraraghavan B; Bakthavatchalam YD; Soman R; Swaminathan S; Manesh A; Nagvekar V; Nangia V
    Indian J Med Microbiol; 2021 Jul; 39(3):286-288. PubMed ID: 33892973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.
    Castón JJ; Lacort-Peralta I; Martín-Dávila P; Loeches B; Tabares S; Temkin L; Torre-Cisneros J; Paño-Pardo JR
    Int J Infect Dis; 2017 Jun; 59():118-123. PubMed ID: 28392315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
    Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA
    Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
    Aitken SL; Tarrand JJ; Deshpande LM; Tverdek FP; Jones AL; Shelburne SA; Prince RA; Bhatti MM; Rolston KVI; Jones RN; Castanheira M; Chemaly RF
    Clin Infect Dis; 2016 Oct; 63(7):954-958. PubMed ID: 27313265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-β-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.
    Senchyna F; Murugesan K; Rotunno W; Nadimpalli SS; Deresinski S; Banaei N
    Clin Infect Dis; 2024 Jun; 78(6):1425-1428. PubMed ID: 38289725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly multidrug-resistant
    Shrestha S; Tada T; Sherchan JB; Uchida H; Hishinuma T; Oshiro S; Morioka S; Kattel H; Kirikae T; Sherchand JB
    J Med Microbiol; 2020 Apr; 69(4):572-575. PubMed ID: 32100711
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases.
    Benchetrit L; Mathy V; Armand-Lefevre L; Bouadma L; Timsit JF
    Int J Antimicrob Agents; 2020 Jan; 55(1):105842. PubMed ID: 31704216
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
    Wenzler E; Deraedt MF; Harrington AT; Danizger LH
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?
    Bocanegra-Ibarias P; Camacho-Ortiz A; Garza-González E; Flores-Treviño S; Kim H; Perez-Alba E
    J Glob Antimicrob Resist; 2020 Dec; 23():417-419. PubMed ID: 33212285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
    Shaw E; Rombauts A; Tubau F; Padullés A; Càmara J; Lozano T; Cobo-Sacristán S; Sabe N; Grau I; Rigo-Bonnin R; Dominguez MA; Carratalà J
    J Antimicrob Chemother; 2018 Apr; 73(4):1104-1106. PubMed ID: 29272413
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of
    Perrotta F; Perrini MP
    Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33924769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by
    Guimarães T; Nouér SA; Martins RCR; Perdigão Neto LV; Martins WMBS; Narciso Barbosa AC; Ferreira ALP; Costa SF; Gales AC
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
    Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
    Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.